Insulin aspart biosimilar - Biocon/Mylan

Drug Profile

Insulin aspart biosimilar - Biocon/Mylan

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocon
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in India (SC)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in India (SC)
  • 13 Feb 2013 Insulin aspart, insulin glargine and insulin lispro biosimilars licensed to Mylan in Australia, Canada, European Union, Iceland, Liechtenstein, New Zealand, Norway, Switzerland, USA and additional countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top